DB2115 tertahydrochloride

Cat. No.: HY-124676A

CAS No.: 1366126-19-3

Molecular Formula: $C_{32}H_{34}Cl_4N_8O_2$

Molecular Weight: 704.48

Target: Apoptosis

Pathway: Apoptosis

Storage: 4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 15.85 mg/mL (22.50 mM; ultrasonic and warming and adjust pH to 4 with HCl and heat to 60°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.4195 mL	7.0974 mL	14.1949 mL
	5 mM	0.2839 mL	1.4195 mL	2.8390 mL
	10 mM	0.1419 mL	0.7097 mL	1.4195 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 1 mg/mL (1.42 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1 mg/mL (1.42 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

DB2115 (tertahydrochloride) is a potent inhibitor of myeloid master regulator PU.1. DB2115 (tertahydrochloride) has the potential for researching cancers, including hematologic cancers such as leukemia, as well as other conditions associated with PU. 1 dysfunction (extracted from patent WO2017223260A1, compound DB2115) [1].

IC_{50} & Target

PU.1[1]

REFERENCES

[1]. W. David Wilson, et al. Pu.1 inhibitors. Patent WO2017223260A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA